Brief: Sarepta Provides Progress Update For Srp-1003, Its Treatment For Myotonic Dystrophy Type 1
24/11/2025 12:43
Nov 24 (Reuters) - Sarepta Therapeutics Inc SRPT.O: SAREPTA PROVIDES PROGRESS UPDATE FOR SRP-1003, ITS INVESTIGATIONAL SIRNA TREATMENT FOR MYOTONIC DYSTROPHY TYPE 1 SAREPTA THERAPEUTICS INC - COHORTS 1 AND 2 COMPLETE, COHORT 3 ONGOING Source text: ID:nBw5dCpTQa Further company coverage: SRPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sarepta Therapeutics
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
U.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
Sarepta, Dyne fall after Novartis muscle disorder trial failure